Amalgamated Bank Has $1.54 Million Stock Holdings in Organon & Co. (NYSE:OGN)

Amalgamated Bank cut its position in shares of Organon & Co. (NYSE:OGN) by 29.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 80,530 shares of the company’s stock after selling 34,385 shares during the quarter. Amalgamated Bank’s holdings in Organon & Co. were worth $1,541,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Versant Capital Management Inc boosted its holdings in Organon & Co. by 200.2% during the second quarter. Versant Capital Management Inc now owns 1,207 shares of the company’s stock valued at $25,000 after purchasing an additional 805 shares in the last quarter. William B. Walkup & Associates Inc. acquired a new stake in Organon & Co. during the second quarter valued at approximately $31,000. Atlas Capital Advisors LLC boosted its holdings in Organon & Co. by 2,236.5% during the second quarter. Atlas Capital Advisors LLC now owns 2,243 shares of the company’s stock valued at $46,000 after purchasing an additional 2,147 shares in the last quarter. Abich Financial Wealth Management LLC boosted its holdings in Organon & Co. by 5,646.3% during the third quarter. Abich Financial Wealth Management LLC now owns 2,356 shares of the company’s stock valued at $45,000 after purchasing an additional 2,315 shares in the last quarter. Finally, Rothschild Investment LLC acquired a new stake in Organon & Co. during the second quarter valued at approximately $54,000. 77.43% of the stock is owned by institutional investors and hedge funds.

Organon & Co. Stock Performance

NYSE:OGN opened at $15.58 on Wednesday. The company has a current ratio of 1.70, a quick ratio of 1.17 and a debt-to-equity ratio of 17.73. The firm has a 50 day moving average of $18.63 and a 200-day moving average of $20.05. Organon & Co. has a 1 year low of $10.84 and a 1 year high of $23.10. The stock has a market capitalization of $4.01 billion, a P/E ratio of 3.09, a price-to-earnings-growth ratio of 0.75 and a beta of 0.84.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Thursday, October 31st. The company reported $0.87 earnings per share for the quarter, missing the consensus estimate of $0.90 by ($0.03). Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The company had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.56 billion. During the same quarter last year, the firm earned $0.78 EPS. The business’s revenue for the quarter was up 4.1% on a year-over-year basis. As a group, sell-side analysts anticipate that Organon & Co. will post 3.89 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 12th. Investors of record on Tuesday, November 12th will be given a $0.28 dividend. This represents a $1.12 annualized dividend and a yield of 7.19%. The ex-dividend date is Tuesday, November 12th. Organon & Co.’s dividend payout ratio (DPR) is presently 22.22%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. JPMorgan Chase & Co. downgraded Organon & Co. from a “neutral” rating to an “underweight” rating and lifted their price objective for the company from $18.00 to $20.00 in a report on Friday, September 6th. Evercore ISI upgraded shares of Organon & Co. to a “strong-buy” rating in a research note on Wednesday, September 18th.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.